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ABSTRACT
Objective: To conduct a secondary analysis of continuation, unwanted effects and cost conse-
quences at 1 year in copper intrauterine device (IUD) users aged under 30 in the European Active
Surveillance Study for Intrauterine Devices (EURAS-IUD study) based on IUD type.
Methods: Descriptive and comparative analyses of copper IUD continuation, unwanted effects and
estimated cost consequences at 1 year were performed in users aged under 30 based on IUD cop-
per surface area, shape or design, width and arms’ flexibility.
Results: 5796 copper IUD users were identified to have been aged under 30 at EURAS-IUD study
recruitment and data for 5762 users (99.4%) was analysed. Higher IUD continuation, fewer
unwanted effects and lower costs were observed with IUDs of the lowest copper content
(<300mm2), horse-shoe frame design, widths 18mm to <30mm and flexible IUD arms.
Discontinuation, unwanted effects and costs were greater with frameless IUDs and framed,
30mm width IUDs with 380mm2 of copper and copper bands on their rigid transverse IUD arms.
Conclusions: Significant differences in continuation, reported unwanted effects and estimated
costs at 1 year between IUD types were observed in users aged under 30. Although further
research is needed, clinicians should consider these findings when counselling and choosing IUD
types for younger women.
ARTICLE HISTORY
Received 8 December 2020
Revised 12 January 2021






Younger women are choosing to use highly effective con-
traceptives [1] resulting in lower birth rates [2]. Most births
in Europe also now occur in the 30–34 age group [2].
Copper intrauterine devices (IUDs) are among the contra-
ceptive options for these women. Consequently, IUDs with
the lowest rates of unwanted effects, discontinuation and
cost should ideally be provided. There are many types of
IUDs currently available in Europe however no publications
identify which of these IUDs are most acceptable to
younger women.
The European Active Surveillance Study for Intrauterine
Devices (EURAS-IUD study) was a multinational prospective
observational study where 61,448 women were provided
with a new intrauterine contraceptive [3,4]. More than 30
different copper IUD brands were fitted in 18,370 partici-
pants and these brands are still available today. Healthcare
professionals (HCPs) from Austria, Finland, Germany,
Poland, Sweden and the United Kingdom recruited partici-
pants to this study and follow up was for at least one year.
We undertook secondary analyses identifying those IUD
users aged 29 or younger at recruitment to the EURAS-IUD
study where the primary outcome was continuation at one
year and secondary outcomes were the incidence of
reported unwanted effects (problems), having to visit a
HCP on account of unwanted effects and estimated cost
consequences by IUD type.
Materials and methods
Study dataset
Descriptions of the EURAS-IUD study and its full dataset
have been previously published [3,4]. For this study, a sub-
set of anonymised one year data on women aged under
30 at the time of copper IUD provision and recruitment to
the EURAS-IUD study was analysed. This dataset contained
information from both HCPs and IUD users that had been
collected from survey questionnaires completed at baseline
and one year follow up. Data included country of recruit-
ment, age at recruitment, obstetric history, brand of IUD
inserted, reports of any unwanted effects or events (prob-
lems including worse bleeding, pain, expulsion, perforation
and pregnancy with the IUD), having visited a HCP on
account of unwanted effects during IUD use, and if the IUD
was still in use at one year follow up (continuation or
use status).
The EURAS-IUD study one year follow up questionnaire
included the following questions: ’Have you had problems
with the IUD?’, ’What are they?’, ’Did you visit a physician
(HCP) because of these problems?’, ’Was the IUD remov-
ed?’, ’Has the IUD fallen out?’… ’Have you been
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pregnant?’, ’Was this pregnancy despite the IUD?’. Women
could therefore report more than one problem experienced
during IUD use.
‘Worse bleeding’ included reports of spotting; heavier,
longer, intermittent, postcoital, and unscheduled bleeding;
and any other unacceptable change in menstrual bleeding.
‘Pain’ included any reports that specified: abdominal, geni-
tal, back or other pain considered to be related to or aris-
ing following the IUD fitting; ‘poking’, ‘pulling’, ‘stinging’,
‘hurting’, ‘cramping’; dysmenorrhoea arising or worsening
following the IUD fitting; and dyspareunia. ‘Infection’
included reported ‘infection’, ‘vaginitis’, ‘adnexitis’,
‘endometritis’, ‘inflammation’, pelvic inflammatory disease,
urinary tract infection, candidiasis, and bacterial vaginosis.
Expulsion included reports of an IUD detected partly or
wholly outside of the uterine cavity, warranting removal.
Perforation included reports of an IUD detected to have
been partially or wholly pierced through the uterus.
Data analysis
Descriptive analyses of the demographics of the total sam-
ple and IUD types are reported. All IUDs were grouped
according to brand or name stated and categorised into
types based on the IUD’s characteristics of copper content,
shape or design, width and IUD arms’ flexibility and
direction. Where IUD type categorisation was not possible
due to missing information, it was described as ‘not speci-
fied’ and excluded from the analysis. [Box 1] Demographics
and IUD types are presented as categorical variables. The
primary outcome of IUD continuation or use at one year
follow up and secondary outcomes of reported unwanted
effects have been presented as binary outcomes based on
IUD type. Percentages for all outcomes and their p-values
are reported. All p-values have been calculated using the
Pearson’s Chi-Square test and Fischer Exact test as appro-
priate and reported at 5% level of significance.
Cost estimations
Economic modelling to estimate IUD cost consequences at
one year based on UK care provision for elements of asso-
ciated resource use [5–7] and managing unwanted effects
[8] was performed. Estimations of costs as a consequence
of an IUD type factored in the price of the IUD, the rates of
expulsion, discontinuation, pregnancy and perforation, and
the incidence of extra visits to a HCP on account of
unwanted effects (extra visits excluded rates for expulsion,
discontinuation, pregnancy and perforation to avoid double
counting or inflating costs).
All IUD provisions were assumed to cost the same,
ignoring any cost differences between participating
Box 1. Brands and characteristics of IUDs provided to EURAS-IUD study participants aged under 30.
IUD brand / name
Number
provided






IUD type by IUD’s
arms’ flexbility
Alphaload 375 48 300 -< 380 X 18-< 24 Yes, flex down
Ancora 7 Not specified X 18 -< 24 Yes, flex down
Ancora 250/375 86 Not specified X 18 -< 24 Yes, flex down
Ancora 375 1 300 -< 380 X 18 -< 24 Yes, flex down
Copper T 380 116 380 Not specified 30 Not specified
Cu safe 22 300 -< 380 T without arm bands 18 -< 24 Yes, flex down
Cu 300/375/380 2 Not specified Not specified Not specified Not specified
Eve’s copper T 380 A/200 B 4 Not specified T not specified 30 No
Femena/femena gold 193 300 -< 380 X 18 -< 24 Yes, flex down
Flexi T 300 57 300 -< 380 T without arm bands 18 -< 24 Yes, flex down
Flexi T 380 273 380 T with arm bands 24 -< 30 Yes, flex down
Gold T 12 300 -< 380 T without arm bands Not specified Yes, flex up
Goldlily 250 1 <300 T without arm bands Not specified Yes, flex up
Goldlily 8 Not specified T without arm bands Not specified Yes, flex up
Gynefix 330 38 300 -< 380 Frameless <18 Not applicable
Gynefix 54 Not specified frameless <18 Not applicable
Gyne T 5 380 T without arm bands 30 No
Gynetics Cu 375 5 300 -< 380 X 18 -< 24 Yes, flex down
Kupferspirale 1 Not specified Not specified Not specified Not specified
Medusa 240 15 <300 X 18 -< 24 Yes, flex down
Mona Lisa 2 380 Not specified 30 Not specified
Multi safe 375 22 300 -< 380 X 18 -< 24 Yes, flex down
Multiload 250 9 <300 X 18 -< 24 Yes, flex down
Multiload 250/375 589 Not specified X 18 -< 24 Yes, flex down
Multiload 375 68 300 -< 380 X 18 -< 24 Yes, flex down
Neo safe 380 84 380 T without arm bands 30 Yes, flex up
Nova T 200 328 <300 T without arm bands 30 Yes, flex up
Nova T 380 1902 380 T without arm bands 30 Yes, flex up
Novagard 200 1 <300 T without arm bands 30 Yes, flex up
Novaplus 29 380 T without arm bands 30 Yes, flex up
Optima IUD TCu 380 A 20 380 T with arm bands 30 No
Pregna copper-T 380 A 3 380 T with arm bands 30 No
SMB Cu 375 1 300 -< 380 X 18 -< 24 Yes, flex down
T 200/375/380 23 Not specified Not specified Not specified Not specified
T de oro / T de plata 161 Not specified T without arm bands 30 Yes, flex up
T safe 380 1287 380 T with arm bands 30 No
TT 380 slimline 275 380 T with arm bands 30 No
TT 380 active 10 380 T with arm bands 30 No
UT 380 32 380 T without arm bands 30 Yes, flex up
Yuan gong 300 1 300 -< 380 Y Not specified Not specified
Yunona bio-T Ag 1 Not specified Y Not specified Not specified
Total 5796
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countries and fitting procedures for all IUD types. However,
IUD brands differed in price. Hence the average IUD price
was calculated per IUD type. The average cost of each IUD
type used in the EURAS-IUD study was calculated using the
UK British National Formulary [7]. Estimated average IUD
prices for the groups of copper content ‘<300mm2’ and
‘380mm2’, ‘unbanded T’ shape or design, ‘30mm’ width
and IUD arms that ‘flex up’ were slightly higher because
these groups included IUD brands like the Nova T380VR
which cost more (£3) than their counterparts. The price
of a Gynefix IUD was up to three times the price of some
other IUDs that were provided to EURAS-IUD study partici-
pants, particularly those IUDs in the group with copper
content ‘300mm2-<380mm2’. To avoid skewing because of
this price difference as well as Gynefix IUDs constituting
1.6% of the IUDs provided and less than 15% of those IUDs
in the copper content ‘300mm2-<380mm2’ group, the
Gynefix IUD price was excluded in the calculation of the
average IUD price for the group of IUDs with copper con-
tent ‘300mm2-<380mm2’.
After their IUD fitting, a user was assumed not to need
to visit a HCP unless she wished to get pregnant, needed
to remove or replace a time-expired IUD, or experienced a
problem (as a consequence of the IUD). Some problems
are expected with an IUD, about which the user would
have been prior counselled e.g. change in period pattern,
heavier and/or more painful periods. These expected prob-
lems could resolve spontaneously within the first few
months of IUD use or they could only occur to a degree
that is tolerated by the user. If problems occurred to a
degree that is not tolerated by the IUD user or required
intervention(s), then the user would usually be expected to
visit a HCP (as a consequence, which will incur additional
cost(s) e.g. of a visit to the HCP).
So unwanted effects like bleeding and pain on their
own were assumed not to incur additional costs after IUD
provision unless the user stated they visited a HCP on
account of these problems. Whereas if the IUD had come
out (expulsion), the user requested IUD removal for reasons
other than to conceive (discontinuation), the user had
become pregnant during IUD use (pregnancy), or perfor-
ation had been detected, an additional cost after IUD pro-
vision was assumed to have been incurred because these
unwanted effects usually required extra HCP visit(s) or
intervention(s).
Costs included for unwanted effects requiring interven-
tions and extra HCP visits have been based on minimum
estimates for healthcare provision in the UK [5,6] and docu-
mented care provision to women with complaints during
their first year of IUD use who attended a UK sexual health
clinic [8]. [Box 2] These outcomes were therefore assumed
to involve consultations with a HCP (e.g. in a family plan-
ning or sexual health clinic) who provided care that
included one or more of the following: screening for sexu-
ally transmitted infections, pregnancy test, urinalysis,
microscopy, transvaginal ultrasound scan, referral e.g. for
termination of pregnancy, and provision of an alternative
method of contraception [8]. With the assumption that
pregnancy with an IUD was unintended, a medical termin-
ation of pregnancy was considered the most likely and
least expensive option where pregnancy was the outcome.
Similarly, an elective laparoscopy procedure as a day case
was considered the intervention where perforation was
the outcome.
Monetary amounts in pounds (£) were derived using
percentage rates of cost-incurring unwanted effects and
extra HCP visits per 100 provisions of each IUD type. These
costs for unwanted effects were then combined with the
IUD costs to obtain the total costs as a consequence of
each IUD type for comparison.
Ethics committee review
Ethical approval was obtained prior to commencement of
the EURAS-IUD study. This secondary analysis was exempt
from the requirement of further ethical review.
Results
Thirty-three percent of IUD users in the EURAS-IUD study
were identified to have been aged under 30 at the time of
recruitment (N¼ 5796) and one year follow up data for
5762 women (99.4%) was included in the analysis
(Figure 1). Majority were 25 to 29 years old (mean age
25.0 years [SD 3.1]), and had previously given birth (66%,
n¼ 3837; mean number of live births 1.6; median
Box 2. Factors and cost estimations as a consequence of IUD provision [5–8]
Outcome / unwanted
effect included in costs
Associated resource use for
outcome / unwanted effect [7,8]
Estimated minimum unit cost
for element(s) of resource
Source of estimated
minimum unit costs
IUD type IUD type fitted in woman by HCP Average price (£) of IUD
brands in IUD type category
British National Formulary [7]
HCP visit Consultation with a HCP ± investigations including
ultrasound scan
£90 National Schedule of
NHS Costs 2018/19 [5]
Expulsion Consultation with a HCP ± IUD removal/ alternative
method provision/ investigations including
ultrasound scan
£90 National Schedule of
NHS Costs 2018/19 [5]
Discontinuation Consultation with a HCP ± IUD removal/ alternative
method provision/ investigations including
ultrasound scan
£90 National Schedule of
NHS Costs 2018/19 [5]
Pregnancy Consultation with a HCP ± IUD removal/ alternative
method provision/ investigations including
ultrasound scan/referral; medical termination
of pregnancy
£419 Unit Costs of Health and
Social Care 2019 [6]
Perforation Consultation with a HCP ± IUD removal/ alternative
method provision/ investigations including
ultrasound scan or x-ray/ referral; laparoscopy to
remove IUD
£752 National Schedule of
NHS Costs 2018/19 [5]
Unit Costs of Health and
Social Care 2019 [6]
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[interquartile range, IQR] number of births 1[0–6]). Most
IUDs provided were framed (98%, n¼ 5704) and the Nova
T380 was the commonest brand of IUD provided. One-third
(32%, n¼ 1868) of all IUDs were T-shaped IUDs with a cop-
per surface area of 380mm2 and copper bands on their
rigid transverse arms (‘gold standard’ IUDs e.g. the
CuT380A or TCu380A). Demographic and IUD type informa-
tion is detailed in Table 1. Previous IUD use was reported
by 1311 women (22.8%).
Continuation at 1 year was highest in those aged
25–29 years and users of IUDs containing <300mm2 of
copper, IUDs with copper only on the vertical stem or
string, and IUDs with flexible arms (Table 2). Continuation
rates were similar irrespective of previous pregnancy or
birth and directly related to age. IUD discontinuation was
therefore associated with being of younger age. There was
no association between participants’ previous IUD use and
continuation at 1 year (p¼ 0.922).
More than a third (35.4%, n¼ 2041) of participants expe-
rienced unwanted effects in the first year of their IUD use,
including: bleeding 1083 (18.8%), pain 973 (16.9%), expul-
sion 190 (3.3%), pregnancy 59 (1.0%), and perforation 6
(0.1%). Unwanted effects were lowest for IUDs with
<300mm2 of copper, of horse-shoe design, and width
18 -< 24mm. Users of IUDs that had 380mm2 of copper,
‘gold standard’ IUDs and frameless IUDs were more likely
to report unwanted effects (Table 3).
Twenty-five percent (n¼ 1470) had visited a HCP on
account of unwanted effects. The incidence of unwanted
effects (29%, n¼ 1503) and having to visit a HCP (17%,
n¼ 891) in those still using their IUD at one year was sig-
nificantly lower (p¼ 0.000) than unwanted effects (93%,
n¼ 538) and having to visit a HCP (100%, n¼ 579) in those
IUD participants aged <30 at recruitment  
N=5796 
Not using IUD at 1 year 
579 (10.1%) 
*Most commonly reported problems: 
Worse bleeding  197 (34.0%) 
Expulsion  190 (32.8%)  
Pain  182 (31.4%) 
Malposition 68 (11.7%) 
Pregnancy  59 (10.2%) 
Infection   36 (6.2%) 
Perforation     6 (1.0%)  
Using IUD at 1 year 
5183 (89.9%)  
*Most commonly reported problems: 
Worse bleeding  886 (17.1%)  
Pain  791 (15.3%) 
Infection   115 (2.2%) 
Discharge  80 (1.5%) 
Partner felt threads 24 (0.5%) 
Threads too long 13 (0.3%)
Lost/missing threads 12 (0.2%) 
IUD removed to conceive before 1 year follow up 
27




Figure 1. EURAS-IUD study participants aged under 30 provided copper intrauterine contraception (IUDs). Participants could report more than one problem.
Table 1. Demographics and IUD types of EURAS-IUD participants aged





Age 18 19 323 5.6
20 24 2008 34.6
25 29 3465 59.8
Pregnancy history Never pregnant 1462 25.2
Ever pregnant 4333 74.8
Birth history No previous (never) birth 496 11.5
Previous (ever) birth 3837 88.5







Copper surface area 380mm2 4038 69.7
300mm2-<380mm2 469 8.1
<300mm2 354 6.1
not specified 935 16.1
IUD shape / design T with arm bands 1868 32.2
T without arm bands 2642 45.6
T not specified 122 2.1
X 1044 18.0
Frameless 92 1.6
Y (ring) 2 0.0
not specified 26 0.5
IUD width in mm <18 92 1.6
18 -< 24 1123 19.4
24 -< 30 273 4.7
30 4259 73.5
Y / ring 2 0.0
not specified 47 0.8
IUD’s arms’ flexibility Yes, flex up 2558 44.1
Yes, flex down 1396 24.1
None 1604 27.7
not specified / applicable 238 4.1
Pregnancy history not stated for 1 participant recruited in Finland.Total for birth history (n¼ 4333) is for participants who have ever
been pregnant.not applicable to frameless and Y/ring IUDs.
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who discontinued IUD use (Tables 4 and 5). Further analysis
of subgroups is presented in Supplemental online material.
For costs estimated as a consequence of the IUD type
per 100 provisions, those IUDs of copper content
<300mm2, horse-shoe design, widths 18 -< 30mm, and
with IUD arms that flex down had the lowest costs while
frameless IUDs had the highest costs. ‘Gold standard’ IUDs
were associated with the highest cost consequences
amongst framed IUD types (Table 6).
There were no statistically significant differences
between the IUD types regarding incidence of pregnancies
in the first year. Eight (13%) of the 59 pregnancies reported
were ectopic pregnancies: six in the 25–29 age group and
two in the 20–24 age group. Five of the ectopic pregnan-
cies were in ‘gold standard’ IUD users, one in a user of a
380mm2 T-shaped without arm bands IUD, and two using
IUDs of copper content 300mm2 -<380mm2, horse-shoe
design, width 18 -<24mm and IUD arms that flex down.
Discussion
Findings and interpretation
Our findings suggest that IUD copper content and size are
key factors for unwanted effects, discontinuation and con-
sequent costs at one year in users aged under 30. Greater
contraceptive dissatisfaction appeared to be mainly influ-
enced by copper content (either copper distribution on the
IUD frame or copper availability in the uterine cavity) and
frame compatibility within the uterus (shape/design, width
and flexibility). The more localised the copper on an IUD
frame and the ability of the frame to conform to the uter-
ine cavity, the more favourable were outcomes at one year.
High contraceptive efficacy was maintained with IUDs of
copper content <300mm2, suggesting uterine cavity size
appeared to also be a factor. The incidence of pregnancy
during IUD use was progressively higher with age, having
ever been pregnant and ever having a live birth. IUD
continuation improving with age could be related to
increasing uterine cavity size improving IUD-cavity compati-
bility; while fewer expulsions associated with IUDs with
flexible arms was possibly because their flexibility sup-
ported IUD movement within the uterine cavity.
Strengths
This is the first comparison study of its kind to determine
which IUD types are more acceptable in younger women.
Its findings are specific to younger aged women at a time
when there is increasing uptake of intrauterine contracep-
tion and less tolerance of unwanted effects. Associations
between modern IUD types and unwanted effects have
been previously reported [9–11] but not between as many
types of IUDs nor in as many younger aged women from
routine clinical practice.
Findings from randomised trials particularly those
involving blinding tend to be rated highest on the hier-
archy of clinical evidence but are not reflective of routine
practice, outcomes or costs for clinician decision-making
and healthcare provision [12–14]. A number of randomised
trials have failed to identify IUD(s) best suited for younger
women, therefore an alternative investigative approach is
required. This secondary analysis of an existing cohort
study provides a low cost approach [15] to support existing
data on IUD use in women aged under 30 [16,17].
The EURAS-IUD study’s prospective observational data
provides the most recent and largest database of its kind
depicting real life experiences with different IUDs. The
study obtained responses from both participants and their
HCPs. The detailed IUD information enabled categorisations
according to IUD copper content, shape or design, width,
and arms’ flexibility as well as estimating IUD prices.
Outcomes including cost consequences in younger and
nulliparous users of different IUDs have never
been reported.
Table 2. IUD continuation or use status at 1 year follow up [%, (n)].
Characteristic Groups Using IUD Not using IUD p-value
Age group N¼ 5762 18 19 87.6 (282) 12.4 (40)
0.01620 24 88.8 (1770) 11.2 (224)
25 29 90.9 (3131) 9.1 (315)
Pregnancy history^ N¼ 5761 Never pregnant 89.7 (1307) 10.3 (150) 0.719
Ever pregnant 90.0 (3875) 10.0 (429)
Birth history^^ n¼ 4304 No previous (never) birth 89.0 (439) 11.0 (54)
0.437Previous (ever) birth 90.2 (3436) 9.8 (375)
IUD type category
Copper surface area (n¼ 4830) 380mm2 89.3 (3580) 10.7 (429)
0.025300mm2 -<380mm2 91.7 (429) 8.3 (39)
<300mm2 93.2 (329) 6.8 (24)
IUD shape/design (n¼ 5612) T with arm bands 88.1 (1636) 11.9 (221)
0.012T without arm bands 91.1 (2388) 8.9 (234)
X 90.2 (939) 9.8 (102)
Frameless 91.3 (84) 8.7 (8)
IUD width in mm (n¼ 5713) <18 91.3 (84) 8.7 (8)
0.92918 -< 24 90.3 (1011) 9.7 (109)
24 -< 30 90.0 (243) 10.0 (27)
30 89.8 (3798) 10.2 (433)
IUD’s arms’ flexibility^^^ (n¼ 5524) Yes, flex up 91.1 (2312) 8.9 (226)
0.002Yes, flex down 90.2 (1254) 9.8 (136)
None 87.8 (1401) 12.2 (195)
Total obtained after excluding participants who wished to conceive and with incomplete/unverified data.All p-values derived using Pearson Chi-square test after excluding Y/ring and non-specified IUD types.IUD categories shown excluding Y/ring and non-specified IUD types.
^Excludes 1 participant for whom pregnancy history not stated.
^^Total for birth history group at follow up (n¼ 4304) is for participants who were ever pregnant.
^^^not applicable to frameless and Y/ring IUDs.
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Weaknesses
Health care provision and participants’ behaviour, e.g.
HCPs’ preferences, IUD types available as well as women’s
autonomy and tolerance for unwanted effects, could differ
across European countries. These may have influenced the
types of IUDs provided, the reporting of unwanted effects,
visiting HCPs, and IUD discontinuation. The UK, Germany,
Finland and Sweden have similar free provision of IUDs
[18]. About half of participants in this study were recruited
from the UK and nearly a quarter from Germany. When
combined with participants from Finland and Sweden, they
made up over 80% of the cohort. Therefore these results
may not be applicable to countries where there is a charge
for IUD provision or their healthcare costs significantly dif-
fer from those of the UK. In this study, there were some
IUD categories that had small numbers which may not be
representative of those IUD types in larger populations.
Groups ‘age 18–190, ‘never pregnant’ and ‘ever pregnant
but no live birth’ also had smaller numbers which may
have been insufficient for significant differences between
IUD types to be detected within these groups in this study.
Other IUDs licenced for use in Europe like the intrauterine
ballVR and smaller-sized framed IUDs like the Neo-safe 380
MiniVR and the Mini TT380 SlimlineVR , which may be recom-
mended for nulliparous and younger aged women, were
not among the IUDs provided to this cohort and hence not
included in this study.
Similarities and differences in relation to other studies
Our findings support the existing literature that in younger
women intrauterine contraceptives are associated with
high continuation and satisfaction rates [19–22] and that
unwanted effects increase IUD discontinuation irrespective
of parity [23–27]. ‘Gold standard’ and frameless IUDs have
higher cost consequences as suggested by more com-
plaints of bleeding, pain and expulsions leading to their
higher discontinuation rates [24–26]. IUDs of horse-shoe
design and with flexible arms were similarly found to
have significantly lower rates of perforation and expul-
sion [28–30].
Previous studies involving younger women have
reported associations between IUD types and outcomes.
The 380mm2 copper IUDs had higher rates of discontinu-
ation and complaints of bleeding, pain and expulsions
compared to IUDs of lower copper content in studies
involving the CuT380A, Cu-safe 300 and Nova T380 [31,32].
Smaller-sized and flexible armed TCu380Ag mini, normal
and maxi IUDs had higher continuation rates, fewer expul-
sions as well as less bleeding and pain when compared
with rigid framed TCu380A IUDs in a randomised trial
involving 600 parous women (mean parity of 2) aged
20–35 [33]. Continuation rates at 12months of 84% and
75.8% for the TCu380Ag and TCu380A groups respectively
were significantly different, and were highest in TCu380Ag
mini IUD users (91.7%) [33]. The rigid framed Gyne T380
Slimline had a significantly higher expulsion rate at one
year compared to the flexible armed Nova T380 IUDs in a
randomised trial involving 957 mainly parous younger
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Uterine cavity size tends to increase with age, preg-
nancy and births [35–37]. Significantly more women aged
under 30 and of parity 2 reported pain with a TCu380Ag
IUD (width 30mm and rigid frame) than with a Multiload
Cu375 IUD (width 18 -< 24mm and flexible arms) in rando-
mised trial involving 1477 women [38]. This finding was
similar to other studies involving the CuT380A, Nova T380,
Multiload 375 and Cu T-safe 300 [31,39].
‘Gold standard’ IUDs (e.g. CuT380A and TCu380A) have
also shown an inverse relationship between age and the
incidence of unwanted effects warranting HCP visits, IUD
removals and cost consequences. A prospective study of
852 primiparous under 30 year olds had higher pain, bleed-
ing, displacement, expulsion, and IUD removal rates in
those 13–19 years compared to those 20–30 years of age,
with bleeding the commonest reason for IUD removal [40].
In an earlier study of over 2000 women with the CuT380A
IUD, expulsion was the commonest reason for discontinu-
ation at one year and with probabilities of expulsion, preg-
nancy and discontinuation for bleeding and/or pain higher
Table 4. Unwanted effects and incidence of visiting a HCP in those participants still using the IUD at 1 year by IUD type.
IUD category Group
Total using
IUD at 1 year
Unwanted
effects
[%, (n)] p Value§
Worse
bleeding
[%, (n)] p Value§
Pain
[%, (n)] p Value§
HCP visit
[%, (n)] p Value§
Copper surface area 380mm2 3580 30.3 (1086) 0.002 18.0 (644) 0.004 16.3 (583) 0.016 17.0 (607) 0.230
300mm2 -<380mm2 429 27.5 (118) 15.9 (68) 14.0 (60) 18.7 (80)
<300mm2 329 21.3 (70) 10.9 (36) 10.6 (35) 14.0 (46)
IUD shape / design T with arm bands 1636 29.3 (479) 0.000 17.5 (286) 0.024 16.0 (261) 0.022 17.5 (286) 0.101
T without arm bands 2388 31.1 (743) 18.1 (432) 16.5 (394) 17.0 (405)
X 939 23.9 (224) 13.8 (130) 12.2 (115) 17.0 (160)
Frameless 84 34.5 (29) 20.2 (17) 15.5 (13) 27.4 (23)
IUD width in mm <18 84 34.5 (29) 0.000 20.2 (17) 0.000 15.5 (13) 0.004 27.4 (23) 0.006
18 -< 24 1011 24.8 (251) 14.3 (145) 13.0 (131) 16.9 (171)
24 -< 30 243 38.3 (93) 26.3 (64) 22.2 (54) 11.1 (27)
30 3798 29.4 (1117) 17.1 (651) 15.5 (589) 17.4 (661)
IUD’s arms’ flexibility Yes, flex up 2312 31.0 (716) 0.031 18.0 (417) 0.245 16.3 (378) 0.306 17.0 (394) 0.149
Yes, flex down 1254 27.4 (344) 16.7 (209) 14.8 (185) 15.8 (198)
None 1401 27.7 (388) 16.0 (224) 14.8 (207) 18.6 (261)
not applicable to frameless and Y/ring IUDs.
§p Values derived using Chi-square test excluding Y/ring and non-specified IUD groups.







[%, (n)] p Value§
Worse
bleeding
[%, (n)] p Value§
Pain
[%, (n)] p Value§
Extra HCP
visitsm
[%, (n)] p Value§
Copper surface area 380mm2 429 92.8 (398) 0.390 36.6 (157) 0.115 34.3 (147) 0.502 0.47 (2) 0.067
300mm2-<380mm2 34 92.3 (36) 30.8 (12) 28.2 (11) 0 (0)
<300mm2 24 100 (24) 16.7 (4) 25.0 (6) 4.17 (1)
IUD shape / design T with arm bands 221 94.6 (209) 0.397 41.6 (92) 0.002 33.0 (73) 0.003 0.90 (2) 0.908
T without arm bands 234 91.9 (215) 32.5 (76) 36.8 (86) 0.43 (1)
X 102 90.2 (92) 20.6 (21) 16.7 (17) 0.98 (1)
Frameless 8 100 (8) 50.0 (4) 37.5 (3) 0 (0)
IUD width in mm <18 8 100 (8) 0.698 50.0 (4) 0.009 37.5 (3) 0.013 0 (0) 0.955
18 -< 24 109 90.8 (99) 23.9 (26) 18.3 (20) 0.92 (1)
24 -< 30 27 92.6 (25) 55.6 (15) 37.0 (10) 0 (0)
30 433 93.3 (404) 34.9 (151) 34.2 (148) 0.69 (3)
IUD’s arms’ flexibility Yes, flex up 226 91.6 (207) 0.330 31.4 (71) 0.123 36.7 (83) 0.014 0.44 (1) 0.779
Yes, flex down 136 91.2 (124) 30.1 (41) 22.1 (30) 0.74 (1)
None 195 94.9 (185) 39.5 (77) 32.3 (63) 1.03 (2)
not applicable to frameless and Y/ring IUDs.
§p-values derived using Chi-square test and Fischer Exact test where applicable excluding Y/ring and non-specified IUD groups.
mExtra HCP visits were HCP visits for unwanted effects excluding expulsion, discontinuation, pregnancy and perforation.
Table 6. Estimated cost consequences (£) at 1 year per 100 provisions by IUD type.
Estimated costs (£) per 100 provisions
IUD category Group IUDs Extra HCP visits Discontinuation Expulsions Pregnancy Perforation Total
Copper surface area 380mm2 1183 958.50 963.00 291.60 460.90 112.80 3969.80
300mm2-<380mm2 918 1116.00 749.70 269.10 716.49 0 3769.29
<300mm2 918 917.10 612.00 127.80 594.98 0 3169.88
IUD shape / design T with arm bands 1076 891.90 1071.00 373.50 494.42 120.32 4027.14
T without arm bands 1327 1081.80 802.80 206.10 431.57 82.72 3931.99
X 391 951.30 882.00 354.60 360.34 0 2939.24
Frameless 2711 1761.30 783.00 488.70 0 0 5744.00
IUD width in mm <18 2711 1761.30 783.00 488.70 0 0 5744.00
18 -< 24 930 956.70 875.70 337.50 372.91 0 3472.81
24 -< 30 947 567.00 900.00 199.80 620.12 0 3233.92
30 1183 1009.80 920.70 288.90 444.14 105.28 3951.82
IUD’s arms’ flexibility Yes, flex up 1327 1089.00 801.00 206.10 427.38 90.24 3940.72
Yes, flex down 933 881.10 880.20 310.50 423.19 0 3427.99
None 1099 946.80 1099.80 405.90 473.47 142.88 4167.85
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in those women aged less than 20 years [41]. Significantly
higher expulsion rates at one year in women <20 years
with the CuT380A IUD were also seen in a similar second-
ary analysis of data on 2748 women from sites in Africa,
Asia and Latin America [42]. IUD evaluations in the US
[43–46], of which one was a retrospective review of health
insurance claims from 90,489 women [46], have revealed
more complaints of dysmenorrhoea and pregnancy as well
as a greater likelihood for HCP contact by teenage
(<20 years) IUD users compared to those IUD
users 20 years.
Relevance of findings: implications for clinicians and
policymakers
This is the first prospective cohort study to help identify
which IUDs best suit women aged under 30 and potential
cost savings in IUD provision. It could also improve contra-
ceptive choice, method continuation and overall wellbeing.
More research is required to substantiate our findings and
this will potentially benefit thousands of younger women
in whom rates of contraceptive discontinuation, unin-
tended pregnancies and abortion tend to be higher.
Our study showed expulsion rates as low as 2% with
some IUD types and an overall ectopic pregnancy risk of
approximately 1 in 1000, reiterating that the IUD is an ideal
contraceptive option for younger aged women. It also
highlights the need for adequate IUD counselling and HCPs
choosing IUD types associated with lower risks of
unwanted effects in these women [47]. The recommenda-
tion of ‘gold standard’ IUDs being first line needs reconsid-
eration for younger aged and nulliparous women. This
could take into account that the ‘gold standard’ IUD’s effi-
cacy appears comparable to IUDs of lower copper content
and different designs in these groups of women, and that
other risks which may have supported such a recommen-
dation, e.g. infection and perforation, are no more as sig-
nificant as they were previously.
Open questions and future research
Our study highlights the need for further research into
how IUD copper content, design and size affect continu-
ation rates, user experiences and care provision costs as a
consequence. Many countries still have only one modern
IUD available, which may be possibly hindering research
comparing IUD types and improvements to current IUDs.
Conclusion
We observed higher continuation rates, fewer unwanted
effects and less associated costs with IUDs containing
<300mm2 of copper, of narrow widths and with flexible
arms in participants aged under 30 recruited to the
EURAS–IUD study. There was no significant difference in
failure rates between IUD types irrespective of pregnancy
history or parity, and IUD discontinuation was associated
with younger age. These findings should support further
research into improving IUD outcomes as well as inform
clinicians’ counselling and IUD type decision-making with
the aim of enhancing continuation, minimising unwanted
effects and potentially reducing costs.
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